查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016585

肌萎縮側索硬化症 (ALS) 治療市場規模、佔有率、趨勢和預測：按 ALS 類型、藥物類型、診斷方法、治療方法、分銷管道和地區分類，2026-2034 年

Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Trends and Forecast by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球肌萎縮側索硬化症（ALS）治療市場規模為8.197億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以3.99%的複合年成長率成長，到2034年達到11.777億美元。目前，北美市場佔據主導地位，預計2025年將佔56.2%的市場。該地區的市場領先地位得益於其完善的醫療保健基礎設施、充足的研究經費以及較高的疾病認知度。此外，該地區還受益於強力的臨床試驗監管支持、尖端治療方法的普及以及完善的醫保報銷政策，所有這些因素都促成了其在ALS治療市場的領先地位。

市場成長的主要驅動力是全球肌萎縮側索硬化症（ALS）發病率的上升，導致對創新治療方法的需求不斷成長。個人化醫療的擴展，以及基因和生物標記研究的進步，使得更具針對性和療效的療法成為可能。近期由倫敦瑪麗女王大學主導的MIROCALS臨床試驗就是這類創新的一個例子。該試驗透過在標準ALS治療方案中加入低劑量白細胞介素-2（IL-2LD）取得了令人鼓舞的結果，顯示其有可能延緩功能衰退並延長存活期。這項試驗凸顯了ALS新治療方法的持續研發。此外，政府為促進罕見疾病治療研發和孤兒藥認定所採取的措施也推動了ALS研究的發展。公共和私營部門投資的增加，以及生物技術公司和製藥公司之間的合作，正在加速新治療方法的發現，從而推動市場擴張。人們對ALS的認知不斷提高，並對其毀滅性影響有了更深入的了解，這也促使人們對治療方法方案的需求不斷成長。

在美國，來自國立衛生研究院 (NIH) 等政府機構和私營部門的大量研究經費正推動著肌萎縮側索硬化症 (ALS) 治療市場的成長。 ALS 認知宣傳活動和支持團體的增加，促使患者活性化參與權益倡導，並提高了對治療方法的需求。此外，尖端基因和細胞療法的研發，以及美國食品藥物管理局(FDA) 的監管支持，正在促進創新。美國大型生物技術和製藥公司的存在，為加速臨床試驗和提高藥物可近性創造了有利環境，進一步推動了市場擴張。

肌萎縮側索硬化症（ALS）治療市場趨勢：

神經系統疾病發生率增加

神經系統疾病盛行率的不斷上升是肌萎縮側索硬化症 (ALS) 治療市場的主要趨勢之一。根據美國國立衛生研究院 (NIH) 2023 年的報告，全球約有 15% 的人口將受到神經系統疾病的影響，而神經系統疾病是導致身體和認知障礙的主要原因。盛行率的上升正在推動對先進 ALS治療方法和干涉措施的需求。隨著人們對神經系統疾病作為一項重大公共衛生問題的認知不斷提高，對專業治療的需求也在增加，宣傳活動不斷推進，醫療創新也在積極推動，以應對與這些疾病相關的挑戰。隨著全球醫療保健系統不斷調整以應對日益加重的神經退化性疾病負擔，預計這一趨勢將持續下去。

人口老化加劇了對肌萎縮側索硬化症（ALS）治療的需求。

全球人口老化對肌萎縮側索硬化症（ALS）治療市場的成長起著至關重要的作用。世界衛生組織（WHO）預測，到2050年，60歲以上人口將達到21億，80歲以上人口將增加至4.26億。由於老年人更容易患有ALS等神經退化性疾病，這種人口結構的變化將推動對專業治療、醫療保健服務和早期診斷的需求成長。隨著醫療保健機構日益關注易患ALS及類似疾病的老年人的需求，不斷成長的老齡人口是影響ALS治療市場前景的關鍵因素。

肌萎縮側索硬化症治療領域的突破性創新

肌萎縮側索硬化症（ALS）治療的進展正對市場產生重大影響，尤其是在正在進行的臨床試驗取得成功之後。例如，2025年4月，NeuroSense Therapeutics公司宣布其用於治療ALS的PARADIGM藥物的IIb期臨床試驗取得了積極成果。該試驗表明，用於治療ALS的在研藥物PrimeC在調節微型RNA展現出顯著療效，有望延緩疾病進展，為ALS患者帶來新的希望。這些突破性進展凸顯了人們對ALS標靶有效治療方法的關注。隨著研究投入的增加和臨床試驗的持續進展，包括基因治療和神經保護方面的試驗，市場正在見證重大進步，這些進步有望在不久的將來徹底改變ALS的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：肌萎縮側索硬化症（ALS）治療的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場細分：依ALS類型分類

  • 散發性肌萎縮性側索硬化症
  • 遺傳性肌萎縮性側索硬化症

第7章 市場區隔：依藥物類型分類

  • 非處方藥
  • 新興藥物

第8章 市場區隔：依診斷類型分類

  • 圖
  • MRI
  • 血液和尿液檢查
  • 腰椎穿刺
  • 肌肉切片檢查

第9章 市場區隔：依治療方式分類

  • 藥物
  • 幹細胞療法
  • 其他

第10章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 其他

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • AB Science
    • Ascend Pharmaceuticals LLC
    • BrainStorm Cell Therapeutics Inc.
    • Corestem Inc.
    • Cytokinetics Inc.
    • Eledon Pharmaceuticals Inc.
    • Ionis Pharmaceuticals Inc.
    • ITF Pharma（Italfarmaco SpA）
    • Mitsubishi Chemical Group Corpotion
    • Revalesio Corporation
    • Treeway BV
Product Code: SR112026A6057

The global amyotrophic lateral sclerosis treatment market size was valued at USD 819.7 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 1,177.7 Million by 2034, exhibiting a CAGR of 3.99% during 2026-2034. North America currently dominates the market, holding a significant market share of 56.2% in 2025. The region leads the market due to robust healthcare infrastructure, extensive research funding, and high disease awareness. The region also benefits from strong regulatory support for clinical trials, access to cutting-edge therapies, and well-established reimbursement policies, contributing to its dominance in the amyotrophic lateral sclerosis treatment market share.

The growth of the market is primarily driven by the increasing demand for innovative therapies due to the rising incidence of ALS worldwide. The expansion of personalized medicine, coupled with advancements in genetic and biomarker research, allows for more targeted and effective treatments. A recent example of such innovation is the MIROCALS clinical trial, led by Queen Mary University of London, which showed promising results by adding low-dose interleukin-2 (IL2LD) to standard ALS treatment, potentially slowing functional decline and extending lifespan. This trial highlights the ongoing development of novel therapies in ALS treatment. Furthermore, government initiatives promoting the development of rare disease treatments and orphan drug designations are encouraging research in ALS. Increased investment from both public and private sectors, alongside collaborations between biotech and pharmaceutical companies, is accelerating the discovery of novel therapies, thus driving market expansion. Enhanced awareness of ALS and its devastating impact also contributes to growing demand for treatment options.

In the United States, the amyotrophic lateral sclerosis treatment market growth is bolstered by strong research funding from both governmental agencies such as the National Institutes of Health (NIH) and private sectors. The rise in ALS awareness campaigns and support groups has led to higher patient advocacy and demand for treatment options. Moreover, the development of cutting-edge gene therapies and cell-based treatments, along with regulatory support from the U.S. Food and Drug Administration (FDA), encourages innovation. The presence of leading biotech and pharmaceutical firms in the U.S. fosters an environment conducive to accelerating clinical trials and improving drug availability, further propelling expansion.

AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET TRENDS:

Rising Incidence of Neurological Disorders

The increasing prevalence of neurological disorders is a key amyotrophic lateral sclerosis treatment market trend. According to a 2023 report by the U.S. National Institutes of Health (NIH), around 15% of individuals globally are affected by neurological conditions, which are the leading cause of physical and cognitive disabilities. This rising incidence is creating a greater need for advanced ALS therapies and interventions. The growing recognition of neurological diseases as a significant public health concern is spurring increased demand for specialized treatments, raising awareness, and fostering medical innovations to address the challenges associated with these disorders. This trend is expected to continue as global healthcare systems adapt to the increasing burden of neurodegenerative diseases.

Expanding Geriatric Population Driving Demand for ALS Treatments

The aging population worldwide is playing a significant role in the growth of the ALS treatment market. By 2050, the World Health Organization (WHO) predicts that the number of people aged 60 and above will reach 2.1 billion, with individuals aged 80 years and over expected to grow to 426 million. As older individuals are more susceptible to neurodegenerative diseases like ALS, this demographic shift will increase the demand for specialized treatments, healthcare services, and early diagnosis initiatives. The expansion of the geriatric population is a key factor influencing the positive amyotrophic lateral sclerosis treatment market outlook, as healthcare providers focus on addressing the needs of an aging population with heightened vulnerability to ALS and similar disorders.

Breakthrough Innovations in ALS Treatment

Advancements in ALS treatment are significantly shaping the market, particularly with the ongoing success of clinical trials. For example, in April 2025, NeuroSense Therapeutics released positive results from its Phase 2b PARADIGM clinical trial for ALS treatment. The trial demonstrated that PrimeC, an experimental ALS treatment, has a notable effect on microRNA modulation, offering new hope for ALS patients by potentially slowing disease progression. Such breakthroughs highlight the growing focus on targeted and effective therapies for ALS. With increasing investment in research and the continued progress of clinical trials, including those focused on gene therapy and neuroprotection, the market is witnessing significant advancements that could revolutionize ALS treatment outcomes in the near future.

AMYOTROPHIC LATERAL SCLEROSIS TREATMENT INDUSTRY SEGMENTATION:

Analysis by ALS Type:

  • Sporadic ALS
  • Familial ALS

Sporadic ALS stand as the largest component in 2025, holding around 68.5% of the market. The sporadic ALS segment dominates the amyotrophic lateral sclerosis (ALS) treatment market due to its higher prevalence compared to familial ALS. This widespread occurrence drives the demand for treatments, research, and healthcare resources dedicated to managing and slowing disease progression. Additionally, the lack of a clear genetic cause in sporadic ALS increases the complexity of treatment, leading to greater focus on developing targeted therapies. Consequently, the large patient population and the need for advanced therapies fuel the market growth in this segment.

Analysis by Drug Type:

  • Marketed Drugs
  • Emerging Drugs

Marketed drugs play a crucial role in the amyotrophic lateral sclerosis (ALS) treatment market by providing immediate solutions to manage the disease's progression. The market is currently driven by FDA-approved therapies such as Rilutek (Riluzole) and Radicava (Edaravone), which help slow ALS progression, extending survival and improving quality of life for patients. As awareness of ALS grows and the demand for effective treatments increases, the marketed drugs segment continues to expand. Enhanced regulatory support, as well as greater insurance coverage, has made these drugs more accessible to a broader patient base. This segment remains pivotal in addressing the unmet needs of ALS patients worldwide, while ongoing research supports the development of next-generation therapies.

Emerging drugs in the ALS treatment market are gaining increasing prominence as researchers focus on innovative therapeutic approaches to address ALS's complex pathology. The emergence of gene therapies, cell-based treatments, and novel oral drugs marks a turning point in ALS management. The development of drugs like PrimeC, currently in clinical trials, demonstrates the potential to modify disease progression through microRNA modulation. Growth drivers for this segment include rising investment in ALS-specific research, advancements in personalized medicine, and the success of early-stage trials. These emerging therapies offer hope for more effective treatments, potentially revolutionizing ALS care by targeting the underlying mechanisms of neurodegeneration.

Analysis by Diagnosis Type:

  • Electromyogram
  • MRI
  • Blood and Urine Tests
  • Spinal Tap
  • Muscle Biopsy

Electromyogram (EMG) plays a crucial role in the diagnosis and management of amyotrophic lateral sclerosis (ALS). It is a primary tool for detecting electrical activity in muscles, allowing healthcare professionals to assess nerve damage, which is a hallmark of ALS. The growing adoption of EMG as a diagnostic tool drives market growth, as early detection is critical for effective disease management. Technological advancements in EMG devices, combined with an increasing number of ALS cases, contribute to its widespread use in clinical settings. Moreover, healthcare awareness and the growing focus on accurate diagnostic procedures further bolster the demand for EMG in ALS treatment.

Magnetic Resonance Imaging (MRI) has become an essential imaging technique for diagnosing and monitoring ALS. While MRI cannot definitively diagnose ALS, it is used to rule out other neurological conditions with similar symptoms, ensuring accurate diagnosis. The use of advanced MRI techniques, such as functional and diffusion tensor imaging, helps in tracking disease progression and monitoring treatment responses. As research into ALS treatments advances, MRI's ability to offer insights into brain and spinal cord abnormalities continues to drive its significance in clinical practice. This growing role in monitoring ALS is spurring the demand for MRI equipment and services within the market.

Blood and urine tests are becoming increasingly important in the diagnosis and monitoring of ALS. These tests help in identifying biomarkers associated with ALS, aiding in early detection and improving disease management. As research into ALS biomarkers advances, blood and urine tests are evolving into essential tools for tracking disease progression and response to treatment. This evolution is driving demand for more advanced diagnostic methods, which is positively impacting the ALS treatment market. The increasing focus on personalized medicine and targeted therapies further emphasizes the importance of blood and urine tests in identifying suitable treatment options for ALS patients.

Analysis by Treatment:

  • Medication
  • Stem Cell Therapy
  • Others

Medication leads the market with around 84.9% of market share in 2025. The medication segment dominates the amyotrophic lateral sclerosis (ALS) treatment market due to the critical role of pharmaceutical therapies in managing the disease. Currently, there are few effective treatment options, making medication essential for slowing disease progression and alleviating symptoms. Drug treatments like riluzole and edaravone are the only FDA-approved options, with ongoing research into new therapies targeting the underlying causes of ALS. As ALS is a progressive neurodegenerative disorder, medications are crucial in extending patients' lifespan and improving quality of life. Furthermore, continued advancements in targeted treatments and clinical trials are further propelling the dominance of the medication segment in the market.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Hospital pharmacies leads the market with around 51.6% of market share in 2025. The hospital pharmacies segment dominates the amyotrophic lateral sclerosis (ALS) treatment market due to their central role in the distribution of specialized medications. Hospitals are primary healthcare settings where ALS patients receive diagnosis, treatment, and continuous care. These pharmacies are equipped with access to advanced drugs, including experimental treatments and those under clinical trials, that are crucial for managing ALS. Furthermore, hospital pharmacies benefit from established relationships with pharmaceutical companies, allowing for faster and more reliable access to ALS therapies. Their ability to provide tailored prescriptions and comprehensive patient management services makes them a key player in the ALS treatment landscape.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 56.2%. North America dominates the amyotrophic lateral sclerosis (ALS) treatment market due to several key factors, including robust healthcare infrastructure, advanced medical research, and high levels of disease awareness. For instance, in July 2025, Klotho Neurosciences' gene therapy candidate, KLTO-202, received orphan drug status from the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). This designation is aimed at supporting the development of treatments for rare diseases. KLTO-202 is designed to deliver instructions for producing a protein that reduces inflammation and oxidative stress, which are critical factors in ALS progression. Preclinical studies have shown that the therapy helps protect nerve cells, improves muscle strength, and slows ALS progression. The company plans to launch a first-in-human trial by the third quarter of 2026, with hopes to further validate its potential as a new ALS treatment. The region benefits from strong support for clinical trials and innovation, with significant investment in ALS research from both public and private sectors. Additionally, comprehensive insurance coverage and well-established reimbursement policies make treatments more accessible to patients. The high incidence of ALS, combined with the growing geriatric population, further increases the demand for specialized care, contributing to North America's dominance in the ALS treatment market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

In 2025, the United States held a market share of around 92% in North America. The United States amyotrophic lateral sclerosis (ALS) treatment market is primarily driven by scientific breakthroughs, regulatory support, and increasing patient advocacy. Advancements in understanding the molecular and genetic underpinnings of ALS, including discoveries related to SOD1 and C9orf72 mutations, are catalyzing the development of targeted therapies such as antisense oligonucleotides, gene therapies, and small-molecule disease modifiers. Regulatory agencies are also streamlining fast-track and orphan drug pathways, which has swiftly translated promising preclinical findings into clinical trials and accelerated approval timelines. For instance, in May 2025, the U.S. Food and Drug Administration (FDA) permitted New York-based BrainStorm Cell Therapeutics Inc. to start the Phase 3b clinical study of its NurOwn (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS). The FDA previously approved the trial design through a Special Protocol Assessment (SPA), ensuring that the study's endpoints and statistical techniques are suitable for the eventual submission of a Biologics License Application (BLA). With this approval, the company can now start enrolling patients for this novel treatment. Additionally, breakthroughs in biomarkers, ranging from imaging modalities to neurofilament proteins, are enabling more precise patient stratification, earlier diagnosis, and improved evaluation of treatment efficacy. Pharmaceutical and biotech investment is also increasing, with numerous collaborations and licensing deals fostering a robust pipeline.

ASIA PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

The Asia Pacific amyotrophic lateral sclerosis (ALS) treatment market is expanding due to scientific advancements, growing healthcare infrastructure, and rising patient awareness. Pharmaceutical and biotech firms are expanding clinical trial operations in the region, leveraging increasingly capable research centers in countries such as Japan, South Korea, China, and Australia to gain access to diverse genetic populations and expedite recruitment. Moreover, public and private sector investments to support innovation in neurodegenerative disease therapies are steadily increasing, creating a favorable environment for the development of new ALS treatment therapies. For instance, in May 2025, Ahmedabad-based Zydus Group successfully secured a Fast Track designation from the U.S. Food and Drug Administration (FDA) for its new neuroinflammatory drug, Usnoflast, for the treatment of amyotrophic lateral sclerosis (ALS). This Fast Track designation highlights the growing need for the development of effective treatment therapies for ALS in India. Expanding diagnostic networks and specialist neurology clinics are also facilitating earlier disease recognition and timely intervention, thereby supporting the adoption of ALS treatment therapies.

EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

The growth of the Europe amyotrophic lateral sclerosis (ALS) treatment market is largely fueled by medical innovations, regulatory alignment, a large number of geriatric population and patient empowerment. In 2024, the EU population was estimated at 449.3 million people and more than one-fifth (21.6%) of it was aged 65 years and over. Scientific advancements in gene editing and RNA therapeutics, particularly antisense oligonucleotides targeting common ALS-associated mutations, are forming the backbone of a growing clinical pipeline, supported by international funding and research consortia. Harmonized regulatory frameworks across the EU, including adaptive approval schemes and orphan designation incentives, are also expediting market entry for breakthrough therapies. Additionally, patient advocacy groups and European ALS registries are playing a central role in clinical trial recruitment and the collection of real-world data. Health technology assessment bodies are increasingly adopting value-based pricing models that consider long-term disease-modifying effects, improving reimbursement prospects for high-cost treatments. Collaborative partnerships between academic institutions, biotech firms, and pharmaceutical companies are fueling translational research, enabling the production and commercialization of novel treatment therapies.

LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

The Latin America amyotrophic lateral sclerosis (ALS) treatment market is experiencing robust growth due to increasing healthcare digitization and increasing awareness among the people in the country. In Brazil, an average of 12,000 patients are diagnosed with ALS each year. As remote care becomes more widely adopted, patients in underserved and rural areas are gaining better access to specialized neurological consultations and ongoing disease management. Public-private collaborations are also supporting investment in rare disease frameworks, creating opportunities for greater funding and awareness. Besides this, efforts to harmonize regulatory standards across countries are streamlining the approval process for innovative treatments, further encouraging market entry.

MIDDLE EAST AND AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

The Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) treatment market is experiencing gradual growth, driven by increasing awareness, improving diagnostic capabilities, and a rise in healthcare investments across the region. As reported, in terms of GDP, the aggregate healthcare expenditure in the KSA increased from 4.4% of GDP in 2001 to 5.97% of GDP in 2021. Although ALS remains a relatively rare neurodegenerative disorder, early detection and the availability of treatment options such as riluzole, edaravone, and supportive therapies are expanding. Countries like the UAE and Saudi Arabia are witnessing enhanced access to specialized neurology care, while collaborations with global pharmaceutical companies are supporting the introduction of advanced treatment options.

COMPETITIVE LANDSCAPE:

The competitive landscape of the amyotrophic lateral sclerosis treatment market is dynamic, with numerous players focused on developing innovative therapies to address unmet needs. Companies are heavily investing in research and development to create new drug classes, particularly targeting neuroprotection and disease-modifying treatments. For instance, in November 2024, Eisai Co., Ltd. launched Rozebalamin(R) for Injection 25 mg (mecobalamin) in Japan for the treatment of amyotrophic lateral sclerosis (ALS), marking a significant milestone in ALS treatment. This drug aims to slow the progression of functional impairment in ALS patients. The approval is based on the successful results of the JETALS Phase III clinical trial, which demonstrated the drug's effectiveness compared to a placebo. Strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are accelerating progress in clinical trials and bringing new treatments to market faster. The growing focus on personalized medicine and biomarkers for early detection further drives competition. As a result, the amyotrophic lateral sclerosis treatment market forecast predicts continued innovation and a rise in the number of treatment options, increasing market competition and expanding opportunities for growth in the coming years.

The report provides a comprehensive analysis of the competitive landscape in the amyotrophic lateral sclerosis treatment market with detailed profiles of all major companies, including:

  • AB Science
  • Ascend Pharmaceuticals LLC
  • BrainStorm Cell Therapeutics Inc.
  • Corestem Inc.
  • Cytokinetics Inc.
  • Eledon Pharmaceuticals Inc.
  • Ionis Pharmaceuticals Inc.
  • ITF Pharma (Italfarmaco S.p.A)
  • Mitsubishi Chemical Group Corpotion
  • Revalesio Corporation
  • Treeway B.V.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the amyotrophic lateral sclerosis (ALS) treatment market?

2. What is the future outlook of the amyotrophic lateral sclerosis (ALS) treatment market?

3. What are the key factors driving the amyotrophic lateral sclerosis (ALS) treatment market?

4. Which region accounts for the largest amyotrophic lateral sclerosis (ALS) treatment market share?

5. Which are the leading companies in the global amyotrophic lateral sclerosis (ALS) treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Amyotrophic Lateral Sclerosis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by ALS Type

  • 6.1 Sporadic ALS
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Familial ALS
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Marketed Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Emerging Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Diagnosis Type

  • 8.1 Electromyogram
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 MRI
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Blood and Urine Tests
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Spinal Tap
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Muscle Biopsy
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Treatment

  • 9.1 Medication
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Stem Cell Therapy
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AB Science
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Ascend Pharmaceuticals LLC
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 BrainStorm Cell Therapeutics Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Corestem Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Cytokinetics Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Eledon Pharmaceuticals Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
    • 16.3.7 Ionis Pharmaceuticals Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 ITF Pharma (Italfarmaco S.p.A)
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
    • 16.3.9 Mitsubishi Chemical Group Corpotion
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Revalesio Corporation
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Treeway B.V.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: Amyotrophic Lateral Sclerosis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by ALS Type (in %), 2025
  • Figure 5: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Drug Type (in %), 2025
  • Figure 6: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Diagnosis Type (in %), 2025
  • Figure 7: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Treatment (in %), 2025
  • Figure 8: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 9: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Amyotrophic Lateral Sclerosis Treatment (Sporadic ALS) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Amyotrophic Lateral Sclerosis Treatment (Sporadic ALS) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Amyotrophic Lateral Sclerosis Treatment (Familial ALS) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Amyotrophic Lateral Sclerosis Treatment (Familial ALS) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Amyotrophic Lateral Sclerosis Treatment (Marketed Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Amyotrophic Lateral Sclerosis Treatment (Marketed Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Amyotrophic Lateral Sclerosis Treatment (Emerging Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Amyotrophic Lateral Sclerosis Treatment (Emerging Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Amyotrophic Lateral Sclerosis Treatment (Electromyogram) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Amyotrophic Lateral Sclerosis Treatment (Electromyogram) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Amyotrophic Lateral Sclerosis Treatment (MRI) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Amyotrophic Lateral Sclerosis Treatment (MRI) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Amyotrophic Lateral Sclerosis Treatment (Blood and Urine Tests) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Amyotrophic Lateral Sclerosis Treatment (Blood and Urine Tests) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Amyotrophic Lateral Sclerosis Treatment (Spinal Tap) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Amyotrophic Lateral Sclerosis Treatment (Spinal Tap) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Amyotrophic Lateral Sclerosis Treatment (Muscle Biopsy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Amyotrophic Lateral Sclerosis Treatment (Muscle Biopsy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Amyotrophic Lateral Sclerosis Treatment (Medication) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Amyotrophic Lateral Sclerosis Treatment (Medication) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Amyotrophic Lateral Sclerosis Treatment (Stem Cell Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Amyotrophic Lateral Sclerosis Treatment (Stem Cell Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Amyotrophic Lateral Sclerosis Treatment (Other Treatments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Amyotrophic Lateral Sclerosis Treatment (Other Treatments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Amyotrophic Lateral Sclerosis Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Amyotrophic Lateral Sclerosis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Amyotrophic Lateral Sclerosis Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Amyotrophic Lateral Sclerosis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Amyotrophic Lateral Sclerosis Treatment (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Amyotrophic Lateral Sclerosis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: North America: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: North America: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United States: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United States: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Canada: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Canada: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Asia-Pacific: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Asia-Pacific: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: China: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: China: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Japan: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Japan: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: India: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: India: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: South Korea: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: South Korea: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Australia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Australia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Indonesia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Indonesia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Europe: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Europe: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Germany: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Germany: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: France: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: France: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: United Kingdom: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: United Kingdom: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Italy: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Italy: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Spain: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Spain: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Russia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Russia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Latin America: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Latin America: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Brazil: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Brazil: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Mexico: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Mexico: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Country (in %), 2025
  • Figure 88: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Global: Amyotrophic Lateral Sclerosis Treatment Industry: SWOT Analysis
  • Figure 90: Global: Amyotrophic Lateral Sclerosis Treatment Industry: Value Chain Analysis
  • Figure 91: Global: Amyotrophic Lateral Sclerosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Amyotrophic Lateral Sclerosis Treatment Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by ALS Type (in Million USD), 2026-2034
  • Table 3: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 4: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Diagnosis Type (in Million USD), 2026-2034
  • Table 5: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Treatment (in Million USD), 2026-2034
  • Table 6: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 7: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Amyotrophic Lateral Sclerosis Treatment Market: Competitive Structure
  • Table 9: Global: Amyotrophic Lateral Sclerosis Treatment Market: Key Players